Edoute Y, Nagachandran P, Svirski B, Ben-Ami H
Department of Internal Medicine C, Rambam Medical Center and The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technlology, Haifa.
J Cardiovasc Pharmacol. 2000 Apr;35(4):556-9. doi: 10.1097/00005344-200004000-00007.
Numerous studies have shown a beneficial effect of combination therapy with beta-blockers and calcium antagonists in patients with anginal syndrome and/or hypertension. However, because both agents exert a negative chronotropic effect, their combined use may cause bradyarrhythmias with resultant symptoms of cerebral, coronary, and systemic hypoperfusion. We describe our clinical experience with patients who had cardiovascular adverse drug reactions (CVADRs) with combination therapy. This prospective study included 26 patients who had CVADRs among 2,574 admissions during a 2-year period. The study group included 14 men and 12 women with a median age of 73 years. Various combinations of calcium antagonists and beta-blockers were associated with the CVADRs. The most frequent pharmacologic combination was diltiazem plus propranolol. The CVADRs were the cause for hospital admission in 10 patients, an associated cause in nine patients, and developed during hospitalization in seven patients. Cardiac bradyarrhythmias were found in 22 patients. These rhythm abnormalities resolved within 24 h after discontinuation of the offending drugs. Temporary transvenous pacemaker insertion was necessary in only one patient with complete atrioventricular block. Twenty-two patients recovered, two patients died of pump failure not associated with CVADRs, and in two patients, the CVADRs contributed to the patients' death. CVADRs are not uncommon in elderly patients with ischemic heart disease and/or hypertension treated with the concomitant use of calcium antagonist and beta-adrenergic blocking drugs. Use of calcium antagonist plus beta-blocker may unpredictably cause serious hemodynamic events, marked suppression of sinus node activity, and prolongation of atrioventricular conduction in some patients. Enhanced therapeutic monitoring may be warranted when calcium antagonists are combined with beta-blockers.
大量研究表明,β受体阻滞剂与钙拮抗剂联合治疗对心绞痛综合征和/或高血压患者具有有益效果。然而,由于这两种药物均具有负性变时作用,它们的联合使用可能会导致缓慢性心律失常,进而引发脑、冠状动脉和全身灌注不足的症状。我们描述了联合治疗出现心血管药物不良反应(CVADR)患者的临床经验。这项前瞻性研究纳入了在2年期间2574例住院患者中出现CVADR的26例患者。研究组包括14名男性和12名女性,中位年龄为73岁。钙拮抗剂和β受体阻滞剂的各种组合与CVADR相关。最常见的药物组合是地尔硫䓬加普萘洛尔。CVADR是10例患者住院的原因,9例患者的相关原因,7例患者在住院期间发生。22例患者发现心脏缓慢性心律失常。停用相关药物后24小时内这些节律异常消失。仅1例完全性房室传导阻滞患者需要临时经静脉起搏器植入。22例患者康复,2例患者死于与CVADR无关的泵衰竭,2例患者中CVADR导致患者死亡。在同时使用钙拮抗剂和β肾上腺素能阻滞剂治疗的老年缺血性心脏病和/或高血压患者中,CVADR并不少见。钙拮抗剂加β受体阻滞剂的使用可能会不可预测地导致严重的血流动力学事件、明显抑制窦房结活动以及某些患者房室传导延长。当钙拮抗剂与β受体阻滞剂联合使用时,可能需要加强治疗监测。